실시간
FierceBiotechNovartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4BPharmaVoiceAmid a flurry of biotech deals, China looks to keep innovation at homeCellPrion-based protein self-assembly tunes mutagenesis to enable rapid adaptationEndpoints NewsEthyreal lands $101M to treat both Graves' and thyroid eye diseaseEndpoints NewsSanofi to mull riliprubart’s future after stopping late-stage nerve disease studyFierceBiotechCancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechsFierceBiotechSanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continueLabiotechBeyond amyloid and dopamine: emerging technologies reshaping neurologyEndpoints NewsParabilis' $670M IPO sets new biotech record, will fund cancer drugeLifeAltered cognitive processes shape tactile perception in autismeLifeCell size modulates ferroptosis susceptibilityClinical OMICsExposure to Moderate Air Pollution Raises Cardiovascular Disease Risk
Endpoints News 2026년 1월 6일

Protagonist 'strongly leaning' toward opting out of Takeda profit-sharing deal

Protagonist 'strongly leaning' toward opting out of Takeda profit-sharing deal

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.